At Janssen Pharmaceutical Companies of Johnson & Johnson, we are working towards a new era for pulmonary arterial hypertension (PAH), aiming to transform the disease into a long-term manageable condition so that patients can live a normal life.

Around 5–10% of patients with adult congenital heart disease (CHD) go on to develop PAH.1 Our goal is to help improve the patient pathway that is delaying patient access to the care they need.

Janssen is a proud sponsor of the British Congenital Cardiac Association (BCCA). Please see below a selection of some of the educational projects we have on offer.

PAH-CHD: Clinical insights from the CHAMPION group

Monday 1st November 2021

13:15–14:00 GMT

Join us at this Janssen-sponsored lunchtime symposium, where the CHAMPION Steering Committee will discuss PAH associated with paediatric CHD and the transition from paediatric to adult services. The expert faculty will present challenging clinical cases, including Eisenmenger syndrome in a patient with Down’s syndrome. We look forward to welcoming you.

Janssen exhibition stand

Visit the Janssen virtual exhibition stand during the conference, where you can chat directly to our knowledgeable representatives.

At the stand, you can watch a video about the achievements and important publications of the CHAMPION Steering Committee to date. You will also find a range of educational materials on the echocardiographic assessment of the right heart, including the EchoRight® mobile app and an opportunity for free access to the Right Heart Masterclass on 123Sonography.

Act on PAH

Continue your learning on the Act on PAH website, developed with pulmonary hypertension specialists to provide practical resources about PAH for healthcare professionals.

  1. Diller G and Gatzoulis M. Circulation 2007;115:1039–50

Developed by Janssen Cilag-Ltd to provide information for UK healthcare professionals only.

October 2021. CP-269037